A lab dedicated to biocompatibility and medical device testing to be based in India's western Gujarat state, a manufacturing hub, would mark a first and has received backing from the federal government with hopes of getting state officials to offer funds as well.
Japan's R-Tech Ueno, which faced a clinical setback this year in ophthalmology even as it sought wider opportunities in the area, has seen U.S.-based Sucampo launch a tender for the firm valued at $278 million overall after the founders agreed to sell their holdings.
In a continued stream of North American deal-making China's Shenzhen Hepalink Pharmaceutical bought U.S.-based biologics contract manufacturer Cytovance Biologics for $205.7 and unspecified contingency payments with plans to accelerate the target's expansion plans.
India's Dr. Reddy's Laboratories says it is poised to move well beyond its core basic generics business into complex products and biosimilars as it looks to widen its reach globally with a focus on the U.S. market.
BeiGene is moving to Suzhou, in part, with plans to branch out from its capital city headquarters and develop a novel oncology drug operation that includes a cGMP manufacturing facility in Suzhou's BioBAY, the company said in a press release.
Three of Mylan-run drug manufacturing operations in India have been cited in a U.S. FDA warning letter for quality violations that included a failure to set procedures aimed at preventing microbiological contamination and on the use of torn gloves..
South African health minister Aaron Motsoaledi wants India to hang tough on intellectual property (IP) challenges for pharmaceuticals because the country's role as a major supplier of affordable medicines needs to be lauded, not scolded.
U.S.-based Abbott Laboratories is among a number of companies that hope to leverage acquisitions in Russia into exports, with other players such as India's Lupin among other potential firms to look to ship wider abroad.
India's top drugmaker and fifth largest in generics globally saw net profit plunge 60% in the first quarter of its financial year as it absorbed costs from its takeover of Ranbaxy Laboratories earlier in 2015, but founder and managing director Dilip Shanghvi pledged that integration would eventually bring greater rewards.
U.S.-based proton therapy system maker Mevion Medical Systems has secured as much as $200 million in financing led by two Chinese Investors, HOPU Investments and YuanMing Capital.